非小细胞肺癌驱动基因介导代谢重编程的研究进展  

Advances in metabolic reprogramming mediated by driver genes in non-small cell lung cancer

作　　者：娄宁 石远凯 韩晓红 Lou Ning;Shi Yuankai;Han Xiaohong(Department of Clinical Laboratory,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Clinical Pharmacology Research Center,Peking Union Medical College Hospital,State Key Laboratory of Complex Severe and Rare Diseases,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100730,China)

机构地区：[1]国家癌症中心国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院检验科、抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021 [2]国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院内科、抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021 [3]中国医学科学院北京协和医学院北京协和医院临床药理研究中心、疑难重症及罕见病国家重点实验室、国家药监局药物临床研究与评价重点实验室、创新药物临床PK/PD北京市重点实验室,北京100730

出　　处：《中国肿瘤临床与康复》2023年第4期213-220,共8页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：国家自然科学基金(81972805);肿瘤内科重点学科研究基金(CICAMSM0MP2022006)。

摘　　要：非小细胞肺癌依靠代谢重编程以满足自身生长和增殖所需。不同的驱动基因变异及肿瘤恶性程度均可导致非小细胞肺癌的代谢异质性,为药物研发带来挑战。因此,阐述驱动基因变异导致代谢重编程的异同,将为药物研发及联合治疗方案制定带来一定的启发,从而改善非小细胞肺癌患者的生存。Non-small cell lung cancer relies on metabolic reprogramming to meet the need of growth and proliferation.Different alteration of driver genes and tumor malignancy can lead to metabolic heterogeneity of non-small cell lung cancer,which brings challenges to drug development.Therefore,elaborating the similarities and differences of metabolic reprogramming caused by alteration of driver genes will bring certain inspiration for drug development and combination therapy to improve the survival of patients with non-small cell lung cancer.

关 键 词：非小细胞肺癌 代谢重编程 Kirsten鼠肉瘤病毒基因同系物 表皮生长因子受体 肝激酶B1 Kelch样环氧氯丙烷相关蛋白-1/核因子E2相关因子2 

分 类 号：R734.2[医药卫生—肿瘤]